Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.51 |
| ▸ | EDNRB | P24530 | 9/20 | 0.51 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.49 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | DHPS | P49366 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.49 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3417934 | 0.89 | EDNRA (0.54) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7935994 | 0.87 | EDNRA (0.57) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL1723227 | 0.85 | EDNRA (0.73) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL20450343 | 0.85 | EDNRA (0.60) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7872328 | 0.83 | EDNRA (0.54) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL14289227 | 0.83 | EDNRA (0.64) | EDNRAEDNRB | |
| SCHEMBL14380593 | 0.83 | EDNRA (0.67) | EDNRAEDNRB | |
| SCHEMBL7851861 | 0.82 | EDNRA (0.49) | EDNRAEDNRB | |
| SCHEMBL1259727 | 0.82 | EDNRA (0.69) | EDNRAEDNRB | |
| SCHEMBL7842038 | 0.81 | EDNRA (0.56) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2240470-A2 | IMPROVED AND NOVEL PROCESS FOR THE PREPARATION OF BOSENTAN | MSN Laboratories Limited (IN) | 2010-10-20 | — | — | EP | claimed |
| EP-2238118-A1 | METHOD OF SYNTHESIS OF BOSENTAN, ITS POLYMORPHIC FORMS AND ITS SALTS | Cipla Limited (IN) | 2010-10-13 | — | — | EP | claimed |
| EP-2205591-A1 | NOVEL POLYMORPHS OF BOSENTAN | Actavis Group PTC EHF (IS) | 2010-07-14 | — | — | EP | claimed |
| WO-2009095933-A2 | IMPROVED AND NOVEL PROCESS FOR THE PREPARATION OF BOSENTAN | MSN LABORATORIES LIMITED (IN) | 2009-08-06 | — | — | WO | claimed |
| WO-2009083739-A1 | METHOD OF SYNTHESIS OF BOSENTAN, ITS POLYMORPHIC FORMS AND ITS SALTS | CIPLA LIMITED (IN) | 2009-07-09 | — | — | WO | claimed |
| WO-2009047637-A1 | NOVEL POLYMORPHS OF BOSENTAN | ACTAVIS GROUP PTC EHF (IS) | 2009-04-16 | — | — | WO | claimed |
| EP-2603497-A1 | A NOVEL PROCESS FOR PREPARATION OF BOSENTAN | Megafine Pharma (P) Ltd. (IN) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020421-A1 | A NOVEL PROCESS FOR PREPARATION OF BOSENTAN | MEGAFINE PHARMA (P) LTD. (IN) | 2012-02-16 | — | — | WO | disclosed |
| EP-2240469-A2 | SUBSTANTIALLY PURE AND A STABLE CRYSTALLINE FORM OF BOSENTAN | Actavis Group PTC EHF (IS) | 2010-10-20 | — | — | EP | disclosed |
| US-20100256371-A1 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND ITS INTERMEDIATES THEREOF | GLENMARK (IN) | 2010-10-07 | — | — | US | disclosed |
| WO-2009093127-A2 | SUBSTANTIALLY PURE AND A STABLE CRYSTALLINE FORM OF BOSENTAN | ACTAVIS GROUP PTC EHF (IS) | 2009-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256371-A1 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND ITS INTERMEDIATES THEREOF | PTGIS, EDNRB, CYP11B2 | EDNRA 6/4885EDNRB 2/4885ABCC3 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.